Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial)
Eiji Oki(Kyushu University), Yoshihiko Maehara(Kyushu University), Dai Manaka(Kyoto Katsura Hospital), Hiroyuki Uetake(National Hospital Organization), Naohiro Tomita(Toyonaka Municipal Hospital), Takeshi Nagasaka(Okayama University), Etsuro Hatano(Kyoto University), Yasunori Emi(Saiseikai Fukuoka General Hospital), Toshiyoshi Fujiwara(Okayama University), Kei Muro(Aichi Cancer Center), Kazuhiro Yoshida(Kyoto Institute of Technology), Michiaki Unno(Tohoku University), Takao Takahashi(Maruyama Memorial General Hospital), Kenichi Sugihara(Toujinkai Hospital), Tetsuya Kusumoto(National Kyushu Medical Center), Yu Katayose(Tohoku Medical and Pharmaceutical University), Takeharu Yamanaka(National Cancer Center Hospital East), Ichinosuke Hyodo(Shikoku Cancer Center), Hitoshi Ojima(Gunma Prefectural Cardiovascular Center)
Cited by 61
Related Papers
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2019|2k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k